SAN FRANCISCO—Men with blood group AB are less likely to develop lethal prostate cancer (PCa) than men with blood type O, researchers reported at the Genitourinary Cancers Symposium.
Yuksel Urun, MD, of the Dana-Farber Cancer Institute in Boston, and colleagues prospectively evaluated the association between ABO blood group and risk of lethal PCa in the Health Professionals Follow-up Study from 1996-2008. A total of 2,793 cases of incidence PCa were documented during 12 years of follow-up of 26,602 men, including 289 lethal cases (either death from PCa or distant metastases). The frequency of ABO blood type was similar between men who developed PCa and other subjects.
On multivariate analysis, blood type was not associated with overall PCa incidence, but compared with men who had blood group O, those with blood group AB were 61% less likely to develop lethal PCa. Compared with blood group O, blood group A or B was not associated with an increased risk of lethal PCa.
Additionally, ABO blood type was not significantly associated with the risk of advanced stage or high-grade cancers (Gleason score 8-10).
The symposium is sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology.